How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Direct oral anticoagulants (DOACs) do not require dose adjustment based on laboratory testing. How- ever, it might be necessary to measure their plasma concentrations in the following specific situations: 1) before thrombolytic therapy in patients with stroke; 2) before surgery or invasive procedure; 3) in case of adverse events (thrombosis or hemorrhage); 4) when immediate reversal of anticoagulation is needed; 5) in patients with extreme body weight; 6) when administering additional drugs potentially interfering with DOACs; and 7) when overdosage is suspected regardless of concomitant bleeding. Basic coagulation tests, such as prothrombin and activated partial thromboplastin time, should not be used as standalone tests to assess the levels of anticoagulation as they are not specific for DOACs and their results are dependent on the type of reagent used for testing. Plasma DOAC concentrations should be assessed by dedicated tests: dilute thrombin time or ecarin tests (for dabigatran) or anti–factor Xa as- says (for anti–factor Xa inhibitors). Dedicated tests should be calibrated against their respective plasma calibrators at certified DOAC concentrations and results should be expressed as ng/ml. Caution should be exerted when interpreting the results of the most common hemostatic parameters such as antithrombin, proteins C and S, lupus anticoagulant, or individual coagulation factors, as they may be strongly affected by the presence of a DOAC. Whenever possible, these parameters should be measured 4 to 5 days after discontinuation of DOAC anticoagulation.

Original languageEnglish
Pages (from-to)379-385
Number of pages7
JournalPolish Archives of Internal Medicine
Volume128
Issue number6
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Anticoagulants
Antithrombin Proteins
Hemorrhage
Thrombin Time
Lupus Coagulation Inhibitor
Blood Coagulation Factors
Partial Thromboplastin Time
Protein S
Thrombolytic Therapy
Prothrombin
Hemostatics
Protein C
Thrombosis
Stroke
Body Weight
Pharmaceutical Preparations

Keywords

  • Activated partial thromboplastin time
  • Anti–factor Xa assay
  • Dilute thrombin time
  • Prothrombin time

ASJC Scopus subject areas

  • Internal Medicine

Cite this

How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues. / Tripodi, Armando; Braham, Simon; Scimeca, Barbara; Moia, Marco; Peyvandi, Flora.

In: Polish Archives of Internal Medicine, Vol. 128, No. 6, 01.01.2018, p. 379-385.

Research output: Contribution to journalReview article

@article{650e8e3f878d429e89b2749b17d48f50,
title = "How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues",
abstract = "Direct oral anticoagulants (DOACs) do not require dose adjustment based on laboratory testing. How- ever, it might be necessary to measure their plasma concentrations in the following specific situations: 1) before thrombolytic therapy in patients with stroke; 2) before surgery or invasive procedure; 3) in case of adverse events (thrombosis or hemorrhage); 4) when immediate reversal of anticoagulation is needed; 5) in patients with extreme body weight; 6) when administering additional drugs potentially interfering with DOACs; and 7) when overdosage is suspected regardless of concomitant bleeding. Basic coagulation tests, such as prothrombin and activated partial thromboplastin time, should not be used as standalone tests to assess the levels of anticoagulation as they are not specific for DOACs and their results are dependent on the type of reagent used for testing. Plasma DOAC concentrations should be assessed by dedicated tests: dilute thrombin time or ecarin tests (for dabigatran) or anti–factor Xa as- says (for anti–factor Xa inhibitors). Dedicated tests should be calibrated against their respective plasma calibrators at certified DOAC concentrations and results should be expressed as ng/ml. Caution should be exerted when interpreting the results of the most common hemostatic parameters such as antithrombin, proteins C and S, lupus anticoagulant, or individual coagulation factors, as they may be strongly affected by the presence of a DOAC. Whenever possible, these parameters should be measured 4 to 5 days after discontinuation of DOAC anticoagulation.",
keywords = "Activated partial thromboplastin time, Anti–factor Xa assay, Dilute thrombin time, Prothrombin time",
author = "Armando Tripodi and Simon Braham and Barbara Scimeca and Marco Moia and Flora Peyvandi",
year = "2018",
month = "1",
day = "1",
doi = "10.20452/pamw.4287",
language = "English",
volume = "128",
pages = "379--385",
journal = "Polskie Archiwum Medycyny Wewnetrznej",
issn = "0032-3772",
publisher = "Medycyna Praktyczna",
number = "6",

}

TY - JOUR

T1 - How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues

AU - Tripodi, Armando

AU - Braham, Simon

AU - Scimeca, Barbara

AU - Moia, Marco

AU - Peyvandi, Flora

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Direct oral anticoagulants (DOACs) do not require dose adjustment based on laboratory testing. How- ever, it might be necessary to measure their plasma concentrations in the following specific situations: 1) before thrombolytic therapy in patients with stroke; 2) before surgery or invasive procedure; 3) in case of adverse events (thrombosis or hemorrhage); 4) when immediate reversal of anticoagulation is needed; 5) in patients with extreme body weight; 6) when administering additional drugs potentially interfering with DOACs; and 7) when overdosage is suspected regardless of concomitant bleeding. Basic coagulation tests, such as prothrombin and activated partial thromboplastin time, should not be used as standalone tests to assess the levels of anticoagulation as they are not specific for DOACs and their results are dependent on the type of reagent used for testing. Plasma DOAC concentrations should be assessed by dedicated tests: dilute thrombin time or ecarin tests (for dabigatran) or anti–factor Xa as- says (for anti–factor Xa inhibitors). Dedicated tests should be calibrated against their respective plasma calibrators at certified DOAC concentrations and results should be expressed as ng/ml. Caution should be exerted when interpreting the results of the most common hemostatic parameters such as antithrombin, proteins C and S, lupus anticoagulant, or individual coagulation factors, as they may be strongly affected by the presence of a DOAC. Whenever possible, these parameters should be measured 4 to 5 days after discontinuation of DOAC anticoagulation.

AB - Direct oral anticoagulants (DOACs) do not require dose adjustment based on laboratory testing. How- ever, it might be necessary to measure their plasma concentrations in the following specific situations: 1) before thrombolytic therapy in patients with stroke; 2) before surgery or invasive procedure; 3) in case of adverse events (thrombosis or hemorrhage); 4) when immediate reversal of anticoagulation is needed; 5) in patients with extreme body weight; 6) when administering additional drugs potentially interfering with DOACs; and 7) when overdosage is suspected regardless of concomitant bleeding. Basic coagulation tests, such as prothrombin and activated partial thromboplastin time, should not be used as standalone tests to assess the levels of anticoagulation as they are not specific for DOACs and their results are dependent on the type of reagent used for testing. Plasma DOAC concentrations should be assessed by dedicated tests: dilute thrombin time or ecarin tests (for dabigatran) or anti–factor Xa as- says (for anti–factor Xa inhibitors). Dedicated tests should be calibrated against their respective plasma calibrators at certified DOAC concentrations and results should be expressed as ng/ml. Caution should be exerted when interpreting the results of the most common hemostatic parameters such as antithrombin, proteins C and S, lupus anticoagulant, or individual coagulation factors, as they may be strongly affected by the presence of a DOAC. Whenever possible, these parameters should be measured 4 to 5 days after discontinuation of DOAC anticoagulation.

KW - Activated partial thromboplastin time

KW - Anti–factor Xa assay

KW - Dilute thrombin time

KW - Prothrombin time

UR - http://www.scopus.com/inward/record.url?scp=85049609389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049609389&partnerID=8YFLogxK

U2 - 10.20452/pamw.4287

DO - 10.20452/pamw.4287

M3 - Review article

VL - 128

SP - 379

EP - 385

JO - Polskie Archiwum Medycyny Wewnetrznej

JF - Polskie Archiwum Medycyny Wewnetrznej

SN - 0032-3772

IS - 6

ER -